Expertise in
32
conditions

Dr. Bayard L. Powell

Oncology
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 
Accepting New Patients
Expertise in
32
conditions
North Carolina Baptist Hospital
1 Medical Ctr Blvd, 
Winston Salem, NC 

Overview

Bayard Powell is an Oncologist practicing medicine in Winston Salem, North Carolina.

Dr. Powell is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Leukemia, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 126 peer reviewed articles and participating in 10 clinical trials. Dr. Powell is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NC

Hospital Affiliations

Wilkes Regional Medical Center
North Carolina Baptist Hospital
Lexington Memorial Hospital Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

North Carolina Baptist Hospital
1 Medical Ctr Blvd, Winston Salem, NC 27103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Study Phase: Phase 3
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring
Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring
Enrollment Status: Completed
Publish Date: August 03, 2026
Intervention Type: Other, Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin Hydrochloride
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase I/II Study of CPI-613 and Hydroxychloroquine for Patients With High Risk MDS Who Have Failed Hypomethylating Therapy
A Phase I/II Study of CPI-613 and Hydroxychloroquine for Patients With High Risk MDS Who Have Failed Hypomethylating Therapy
Enrollment Status: Withdrawn
Publish Date: April 14, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 9 Less Clinical Trials

126 Total Publications

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Journal: Leukemia
Published: March 31, 2026
Similar Doctors
Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Atrium Health Wake Forest Baptist

S Hawthorne Rd, 
Winston Salem, NC 
 (1.5 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Glenn Lesser is an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Lesser is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, Glioma, and Bone Marrow Aspiration. Dr. Lesser is currently accepting new patients.

Expertise in
16
conditions
Dr. Matthew J. Wieduwilt
Hematology | Oncology
Expertise in
16
conditions
Dr. Matthew J. Wieduwilt
Hematology | Oncology
Referral may be required

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-713-5440
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Wieduwilt is a Hematologist and an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Wieduwilt is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Wieduwilt is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request

North Carolina Baptist Hospital

1 Medical Ctr Blvd, 
Winston Salem, NC 
 (0.1 miles away)
336-713-6178
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samuel Lentz is an Oncologist practicing medicine in Winston Salem, North Carolina. Dr. Lentz is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Lymphadenectomy, and Bladder Reconstruction. Dr. Lentz is currently accepting new patients.

Frequently Asked Questions about Dr. Bayard L. Powell

How do I make an appointment with Dr. Bayard L. Powell?

You can book an appointment with Dr. Bayard L. Powell by calling their office at 336-713-5440. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bayard L. Powell a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bayard L. Powell is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bayard L. Powell specialize in?

While Dr. Bayard L. Powell is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Bayard L. Powell participate in research or clinical trials?

Yes. Dr. Bayard L. Powell has published 126 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Bayard L. Powell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bayard L. Powell accept my insurance?

Dr. Bayard L. Powell accepts most major insurance plans, including Aetna and AmeriHealth. We recommend calling the office directly at 336-713-5440 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Powell's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 19 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile